Lau Kolja, Sokalski Victoria, Lorenz Lora, Fette Georg, Sommer Claudia, Üçeyler Nurcan, Wanner Christoph, Nordbeck Peter
Department of Internal Medicine I, Universitätsklinikum Würzburg, Würzburg, BY, Germany.
Fabry Center for Interdisciplinary Therapy (FAZiT), Universitätsklinikum Würzburg, Würzburg, BY, Germany.
Open Heart. 2025 Jan 11;12(1):e003116. doi: 10.1136/openhrt-2024-003116.
Hypertrophic cardiomyopathy (HCM) has various aetiologies, including genetic conditions like Fabry disease (FD), a lysosomal storage disorder. FD prevalence in high-risk HCM populations ranges from 0.3% to 11.8%. Early diagnosis of FD is crucial due to available treatments, but its rarity and diverse symptoms complicate identification. Heart-specific FD variants often lead to late diagnoses due to the absence of typical FD symptoms. This prospective study (NCT04943991) was conducted to identify patients with undiagnosed FD using electronic health records (EHR) at a German tertiary-care hospital.
Over 20 years (2000-2020), 2824 patients with 'left ventricular hypertrophy (LVH)' or 'hypertrophic cardiomyopathy (HCM)' were identified by full-text search. Exclusion criteria were age over 85, other diagnosed cardiomyopathies, significant valvular heart disease, death, active malignancy and prior FD testing. The remaining patients received an invitation for FD genetic testing.
Of the 2824 identified patients, 2626 (93%) fulfilled the exclusion criteria. Among the 198 included patients, 96 responded, and 55 underwent genetic testing, yielding a response rate of 48% and a testing rate of 28%. In one patient (1.8% of tested), FD was diagnosed with the variant. Subsequent family screening revealed six additional FD cases, with four initiating FD-specific therapies. Comprehensive clinical evaluations were conducted in five of the seven identified patients.
Genetic testing of patients with unexplained LVH/HCM using EHR is effective for identifying FD. Subsequent family screening further identified at-risk individuals, promoting regular follow-ups and if needed FD-specific therapies. This approach highlights the potential for broader application in high-risk populations to uncover treatable genetic conditions. The next phase should focus on automating the executed search process.
NCT04943991.
肥厚型心肌病(HCM)有多种病因,包括像法布里病(FD)这样的遗传性疾病,后者是一种溶酶体贮积症。高危HCM人群中FD的患病率在0.3%至11.8%之间。由于有可用的治疗方法,FD的早期诊断至关重要,但其罕见性和多样的症状使识别变得复杂。心脏特异性FD变异体由于缺乏典型的FD症状,常常导致诊断延迟。这项前瞻性研究(NCT04943991)在一家德国三级护理医院开展,旨在利用电子健康记录(EHR)识别未确诊FD的患者。
在20年(2000 - 2020年)期间,通过全文搜索识别出2824例患有“左心室肥厚(LVH)”或“肥厚型心肌病(HCM)”的患者。排除标准为年龄超过85岁、其他已确诊的心肌病、严重瓣膜性心脏病、死亡、活动性恶性肿瘤以及既往FD检测。其余患者收到FD基因检测邀请。
在2824例识别出的患者中,2626例(93%)符合排除标准。在198例纳入患者中,96例做出回应,55例接受了基因检测,回应率为48%,检测率为28%。在1例患者(占检测患者的1.8%)中,通过该变异体诊断出FD。随后的家族筛查又发现了6例FD病例,其中4例开始接受FD特异性治疗。在7例已识别患者中的5例进行了全面的临床评估。
利用EHR对不明原因LVH/HCM患者进行基因检测对于识别FD是有效的。随后的家族筛查进一步识别出高危个体,促进定期随访,并在需要时进行FD特异性治疗。这种方法凸显了在高危人群中更广泛应用以发现可治疗遗传性疾病的潜力。下一阶段应专注于将执行的搜索过程自动化。
NCT04943991。